Press Releases Essex Bio-Technology Limited

Equities

1061

KYG312371035

Market Closed - Hong Kong S.E. Other stock markets 01:38:35 13/05/2024 pm IST			5-day change	1st Jan Change
2.58 ^HKD	+8.40%		+7.95%	+3.61%

19/03	Essex Bio-Technology's 2023 Profit Jumps 22% on Higher Turnover	MT
18/03	Essex Bio-Technology Limited Proposes Final Ordinary Dividend for the Financial Year Ended 31 December 2023, Payable June 17, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Essex Bio-Technology Posts Sound 2023 Annual Financial Results, Revenue Up 29.5%, Profit Up 22.1%	18/03	AQ
Essex Bio-Technology Posts Sound 2023 Interim Financial Results, Revenue Up 37.1%, Profit Up 22%	16/23/16	AQ
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed	26/23/26	AQ
Essex and Osteopore Entered into Exclusive Distribution Agreement	14/23/14	AQ
Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore	14/23/14	AQ
Essex and Gunze Shenzhen Entered into Exclusive Agency Agreement for PELNAC Absorbable Dressing in Mainland China	11/23/11	AQ
Essex Bio-Technology Announces 2022 Annual Financial Results	08/23/08	AQ
Essex and Henlius signed amendment agreement for Global Co-Development and Exclusive License Agreement for treatment of age-related macular degeneration	22/23/22	AQ
First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases	11/23/11	AQ
Essex Biotechnology Secures Exclusive Global Rights	14/22/14	AQ
Essex Biotechnology Secures Exclusive Global Rights and Interests of SkQ1 in the field Ophthalmology from Mitotech	13/22/13	AQ
Essex Bio-Technology Included in "Forbes Asia's Best Under A Billion 2022"	16/22/16	AQ
Essex Bio-Technology Announces 2021 Financial Results	22/22/22	AQ
Essex Bio Technology : NEXT DAY DISCLOSURE RETURN	17/21/17	PU
Essex Bio Technology : 2020 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT	07/21/07	PU
Essex Bio Technology : VOLUNTARY ANNOUNCEMENT FURTHER UPDATE IN RELATION TO THE CO-DEVELOPMENT OF THE LICENSED PRODUCT WITH HENLIUS RELATING TO THE TREATMENT OF EXUDATIVE (WET) AGE-RELATED MACULAR DEGENERATION	20/21/20	PU
Essex Bio Technology : INSIDE INFORMATION APPROVAL TO COMMERCIALISE PRESERVATIVE-FREE UNIT-DOSE MOXIFLOXACIN HYDROCHLORIDE EYE DROPS IN THE PRC	07/21/07	PU
Essex Bio Technology : FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON WEDNESDAY, 12 MAY 2021 (or any adjournment thereof)	25/21/25	PU
Essex Bio Technology : PROPOSALS FOR GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES, RE-ELECTION OF DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING	25/21/25	PU
Essex Bio Technology : VOLUNTARY ANNOUNCEMENT FURTHER UPDATE IN RELATION TO THE CO-DEVELOPMENT OF THE LICENSED PRODUCT WITH HENLIUS RELATING TO THE TREATMENT OF EXUDATIVE (WET) AGE-RELATED MACULAR DEGENERATION	19/21/19	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Essex Bio-Technology Limited

Equities

1061

KYG312371035

Press Releases

Filters